Findings

What do systematic reviews say?

5 questions · 5 findings · 1 reviews

No studies found 4 · 80%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 20%Moderate 0 · 0%High 0 · 0%

Proportion of people with ≥ 1 serious adverse events during treatment · participants with unresectable hepatocellular carcinoma

The review found no eligible studies for this question.

1 finding from 1 review

Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Disease progression · participants with unresectable hepatocellular carcinoma

The review found no eligible studies for this question.

1 finding from 1 review

Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

All‐cause mortality · participants with unresectable hepatocellular carcinoma

Double‐dose adenovirus‐thymidine kinase with ganciclovir… may leads to lower all‐cause mortality compared with liver transplantation (low certainty).

1 finding from 1 review

Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only
RR 0.4 [0.22, 0.73]
1 study · 86 participants
Low

Health‐related quality of life · participants with unresectable hepatocellular carcinoma

The review found no eligible studies for this question.

1 finding from 1 review

Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Adverse events considered non‐serious · participants with unresectable hepatocellular carcinoma

The review found no eligible studies for this question.

1 finding from 1 review

Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found